The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development
about
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionFactors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trialsImpact of ABCB1 allelic variants on QTc interval prolongation.Drug Delivery: Enabling Technology for Drug Discovery and Development. iPRECIO Micro Infusion Pump: Programmable, Refillable, and Implantable.A pharmacogeneticist's look at drug effects and the drug development process: an overview.Pharmacogenomics: challenges and opportunitiesEthics at phase 0: clarifying the issues.Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I-Comparison between Healthy Subjects and Patients with Hypertension.Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.Emerging therapeutic approaches in the management of retinal angiogenesis and edema.In vivo rat PK profiling in drug discovery: new challenges.Impact of preformulation on drug development.The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments.Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.Quantitative organ time activity curve extraction from rodent PET images without anatomical prior.The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects.Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10.Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.CYP2D6 gene test in psychiatric patients and healthy volunteers.Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokineticsIdentification of beagle food taking patterns and protocol for food effects evaluation on bioavailability
P2860
Q31146882-FF7EF43C-99AF-493B-993B-3DC55FF6EC22Q33849108-531D3462-D5D0-4E0E-82E6-A8C3CD265C8BQ34152280-88E0119A-C3C9-4E7C-8CA6-D4BE33A6FF29Q34781769-9C025445-3B42-4068-B67E-A4AF742A87F1Q35144336-5BFF5409-298C-453A-BA6C-D0C335DF088EQ36192744-E03E82E1-7F0E-4EDB-B8EC-1A256B905B68Q36658763-BC89539C-7979-4405-8FF2-F0EEBC580223Q37030959-FD792DFC-89CB-467D-9318-1E384A0A355AQ37280941-756F104C-577B-4966-BEAD-1A734FA4D20CQ37810137-298F787E-4C50-4FD3-849D-03213CDB79A0Q37822290-F81D4DAF-BECF-42BA-96C3-CDD030070690Q38029116-BC1012D7-0194-4311-A547-098BFFA5B862Q38093663-41579A76-93EE-4B49-A6C0-6B6FB9C87441Q39018559-D890825D-0916-483A-A740-B1A9EA5D4F74Q41820935-AC5F75C6-24DE-40B9-AE1C-B2CE0A70DD20Q43073752-FC5D765D-0121-4E77-B2E4-DA9D2072611AQ43932577-646EFDA2-D49C-40A7-B2D3-2602FEB845EAQ45111558-61B18F6F-0ABC-4206-B4BE-275490D67B7FQ47164733-34180897-4C90-484D-A5B5-344E3F392478Q47946666-F2DEFBA0-98DA-40D8-B3E2-FC06E2B4930FQ51920384-D592D9C1-040B-4F86-9467-5E768EE97A71Q56430923-9D310448-EBF5-447B-BE33-7AD2FD17B47CQ58707484-0A6DA687-14C4-4620-AFFF-57763BBD1AF4
P2860
The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The use of pharmacokinetic and ...... fety in early drug development
@ast
The use of pharmacokinetic and ...... fety in early drug development
@en
type
label
The use of pharmacokinetic and ...... fety in early drug development
@ast
The use of pharmacokinetic and ...... fety in early drug development
@en
prefLabel
The use of pharmacokinetic and ...... fety in early drug development
@ast
The use of pharmacokinetic and ...... fety in early drug development
@en
P2860
P1476
The use of pharmacokinetic and ...... fety in early drug development
@en
P2093
D K Walker
P2860
P304
P356
10.1111/J.1365-2125.2004.02194.X
P407
P577
2004-12-01T00:00:00Z